George Simeon 4

What Happened

• George Simeon, a director of CRISPR Therapeutics (CRSP), was granted 13,000 derivative shares (reported as a grant/award) on 2026-06-05. The reported acquisition price is $0.00 (derivative security), so no cash was paid on grant.
• This is an equity compensation award (not an open-market purchase or sale).

Key Details

• Transaction date: 2026-06-05; Form 4 filed: 2026-06-09 (filed within the required two business days).
• Amount granted: 13,000 derivative shares/options; price reported: $0.00; total reported cash outlay: $0.00.
• Shares owned after the transaction: not specified in the provided filing.
• Footnote: the award are options that vest and become exercisable in 12 equal monthly installments, with the first vesting on June 30, 2026, and the final installment vesting on the earlier of the one-year anniversary of grant or the 2027 Annual Meeting.
• Transaction code: A (grant/award). No 10b5-1 plan, tax withholding, or late-filing indication noted in the filing summary provided.

Context

• This is a standard time‑based equity grant to a director as compensation; it is not an immediate cash purchase or sale and does not indicate an immediate sale of shares.
• Because these are options that vest over the next year, the award is intended to align long-term interests but does not by itself signal insider buying or selling behavior in the market.